Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Free Subscription

Articles published in Ann Hematol

Retrieve available abstracts of 305 articles:
HTML format

Single Articles

    May 2020
  1. SCALZULLI E, Colafigli G, Latagliata R, Pepe S, et al
    Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
    Ann Hematol. 2020 May 28. pii: 10.1007/s00277-020-04096.
    PubMed     Abstract available

  2. CHEN Q, Zhao X, Fu HX, Chen YH, et al
    Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia.
    Ann Hematol. 2020 May 26. pii: 10.1007/s00277-020-04080.
    PubMed     Abstract available

  3. MAAKARON JE, Ozga MP, Mannis GN, Pulley W, et al
    Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
    Ann Hematol. 2020 May 6. pii: 10.1007/s00277-020-04054.

  4. YANADA M, Takami A, Yamasaki S, Arai Y, et al
    Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.
    Ann Hematol. 2020 May 4. pii: 10.1007/s00277-020-04051.
    PubMed     Abstract available

    April 2020
  5. HELBIG G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, et al
    Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
    Ann Hematol. 2020 Apr 24. pii: 10.1007/s00277-020-04026.
    PubMed     Abstract available

  6. HORISAWA Y, Kondo T, Hishizawa M, Yamashita K, et al
    A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
    Ann Hematol. 2020 Apr 21. pii: 10.1007/s00277-020-04029.

  7. BRUMMENDORF TH, Gambacorti-Passerini C, Bushmakin AG, Cappelleri JC, et al
    Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04018.
    PubMed     Abstract available

  8. GAO M, Zhao X
    Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04037.

  9. GUPTA C, Kaulfuss S, Gorlich K, Othman B, et al
    Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Ann Hematol. 2020 Apr 15. pii: 10.1007/s00277-020-04001.

  10. MIN GJ, Cho BS, Park SS, Park S, et al
    Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Ann Hematol. 2020 Apr 8. pii: 10.1007/s00277-020-04010.
    PubMed     Abstract available

  11. SPIESS B, Kleiner H, Flach J, Fabarius A, et al
    Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients.
    Ann Hematol. 2020 Apr 6. pii: 10.1007/s00277-020-04007.
    PubMed     Abstract available

  12. APEL A, Ofran Y, Wolach O, Shimony S, et al
    Safety and efficacy of blinatumomab: a real world data.
    Ann Hematol. 2020;99:835-838.
    PubMed     Abstract available

  13. BUSSAGLIA E, Pratcorona M, Carricondo M, Sansegundo L, et al
    Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).
    Ann Hematol. 2020;99:765-772.
    PubMed     Abstract available

    March 2020
  14. OZBAGCIVAN O, Akarsu S, Nazli EC, Lebe B, et al
    Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 27. pii: 10.1007/s00277-020-04009.

  15. VAN DER STRATEN L, Kater AP, Doorduijn JK, van den Broek EC, et al
    Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03994.
    PubMed     Abstract available

  16. PERINGETH G, Sundaram S, Bogner P, Conroy E, et al
    Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03991.

  17. ERNST P, Engmann B, Frietsch JJ, Schnetzke U, et al
    A 19-year-old patient with atypical chronic myeloid leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03992.

  18. MASSAIU R, Longu F, Podda L, Mura F, et al
    Rectal involvement in pre-early T acute lymphoblastic leukemia.
    Ann Hematol. 2020 Mar 16. pii: 10.1007/s00277-020-03998.

  19. SORIGUE M, Espasa A, Zamora L, Junca J, et al
    Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Ann Hematol. 2020 Mar 13. pii: 10.1007/s00277-020-03997.

  20. TAKEUCHI M, Miyoshi H, Nakashima K, Kawamoto K, et al
    Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
    Ann Hematol. 2020 Mar 10. pii: 10.1007/s00277-020-03967.
    PubMed     Abstract available

  21. XIE W, Tang G, Wang E, Kim Y, et al
    t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
    Ann Hematol. 2020;99:487-500.
    PubMed     Abstract available

  22. PABST G, Lind K, Graf R, Zebisch A, et al
    TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
    Ann Hematol. 2020;99:653-655.

  23. MARTIN I, Navarro B, Serrano A, Villamon E, et al
    Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
    Ann Hematol. 2020;99:527-537.
    PubMed     Abstract available

  24. ALKHARABSHEH O, Patnaik MM, Gangat N, Begna KH, et al
    Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
    Ann Hematol. 2020;99:513-518.
    PubMed     Abstract available

  25. ANZEJ DOMA S, Skerget M, Pajic T, Sever M, et al
    Improved survival of AML patients by addition of cladribine to standard induction chemotherapy.
    Ann Hematol. 2020;99:519-525.
    PubMed     Abstract available

  26. HEITMANN JS, Hagelstein I, Hinterleitner C, Roerden M, et al
    Identification of CD318 (CDCP1) as novel prognostic marker in AML.
    Ann Hematol. 2020;99:477-486.
    PubMed     Abstract available

  27. KONTOPOULOU E, Strachan S, Reinhardt K, Kunz F, et al
    Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics.
    Ann Hematol. 2020;99:459-475.
    PubMed     Abstract available

    February 2020
  28. TING S, Mixue X, Lixia Z, Xueying L, et al
    T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ann Hematol. 2020 Feb 27. pii: 10.1007/s00277-020-03949.
    PubMed     Abstract available

  29. BOUCHACOURT B, Hospital MA, Zemmour C, Rey J, et al
    Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
    Ann Hematol. 2020 Feb 22. pii: 10.1007/s00277-020-03922.
    PubMed     Abstract available

  30. LUBER V, Lutz M, Thiede C, Haferlach C, et al
    Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation.
    Ann Hematol. 2020 Feb 22. pii: 10.1007/s00277-020-03905.

  31. SCHIECK M, Lentes J, Thomay K, Hofmann W, et al
    Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
    Ann Hematol. 2020 Feb 20. pii: 10.1007/s00277-020-03953.
    PubMed     Abstract available

  32. GRUHN B, Brodt G, Wittig S, Ernst T, et al
    Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL.
    Ann Hematol. 2020 Feb 18. pii: 10.1007/s00277-020-03957.

  33. HAN Q, Tao L, Jiang X, Chen H, et al
    An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium.
    Ann Hematol. 2020 Feb 13. pii: 10.1007/s00277-020-03961.

  34. RADUJKOVIC A, Hegenbart U, Muller-Tidow C, Herfarth K, et al
    High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
    Ann Hematol. 2020 Feb 8. pii: 10.1007/s00277-020-03952.
    PubMed     Abstract available

  35. CONTIERI B, Duarte BKL, Lazarini M
    Updates on DNA methylation modifiers in acute myeloid leukemia.
    Ann Hematol. 2020 Feb 6. pii: 10.1007/s00277-020-03938.
    PubMed     Abstract available

  36. KIDOGUCHI K, Yokoo M, Umino A, Aoki S, et al
    Terminal deoxynucleotidyl transferase (TdT) negative early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with spontaneous acute kidney injury.
    Ann Hematol. 2020 Feb 5. pii: 10.1007/s00277-020-03943.

  37. CHEN S, Li X, Ma S, Xing X, et al
    Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia.
    Ann Hematol. 2020 Feb 4. pii: 10.1007/s00277-019-03888.
    PubMed     Abstract available

  38. RASSIDAKIS GZ, Stromberg O, Xagoraris I, Jatta K, et al
    Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation.
    Ann Hematol. 2020 Feb 3. pii: 10.1007/s00277-020-03941.

  39. OJHA S, Ooi MG
    Pregnancy exposure to midostaurin in the first trimester.
    Ann Hematol. 2020;99:355-356.

  40. SIM JPY, Au-Yeung R, Kwong YL
    Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
    Ann Hematol. 2020;99:385-388.

    January 2020
  41. HIROSAWA M, Yamaguchi T, Tanaka A, Kominato Y, et al
    Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
    Ann Hematol. 2020 Jan 31. pii: 10.1007/s00277-020-03934.
    PubMed     Abstract available

  42. WANG YW, Tsai CH, Lin CC, Tien FM, et al
    Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
    Ann Hematol. 2020 Jan 21. pii: 10.1007/s00277-020-03911.
    PubMed     Abstract available

  43. SONG JX, Wen Y, Li RW, Dong T, et al
    Phenotypic characterization of macrophages in the BMB sample of human acute leukemia.
    Ann Hematol. 2020 Jan 18. pii: 10.1007/s00277-020-03912.
    PubMed     Abstract available

  44. LI M, Cui X, Guan H
    MicroRNAs: pivotal regulators in acute myeloid leukemia.
    Ann Hematol. 2020 Jan 13. pii: 10.1007/s00277-019-03887.
    PubMed     Abstract available

  45. FREYNET N, Tarfi S, Badaoui B, Leclerc M, et al
    Acute myelomonocytic leukemia with uncommon morphological features.
    Ann Hematol. 2020 Jan 8. pii: 10.1007/s00277-019-03883.

  46. WANG XR, Chang Y, Yuan XY, Wang YZ, et al
    Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia.
    Ann Hematol. 2020 Jan 4. pii: 10.1007/s00277-019-03808.
    PubMed     Abstract available

    December 2019
  47. ZHANG X, Li J, Jin J, Yu W, et al
    Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
    Ann Hematol. 2019 Dec 26. pii: 10.1007/s00277-019-03902.

  48. MORI H, Sukegawa M, Fukatsu M, Sano T, et al
    The link between interleukin-1beta and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
    Ann Hematol. 2019 Dec 23. pii: 10.1007/s00277-019-03896.

  49. BRAVO-PEREZ C, Pajares I, Muina B, Escobar H, et al
    Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
    Ann Hematol. 2019 Dec 20. pii: 10.1007/s00277-019-03897.

  50. PAGANO L, Maraglino AME, Fianchi L, Criscuolo M, et al
    Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT.
    Ann Hematol. 2019 Dec 12. pii: 10.1007/s00277-019-03885.

  51. KHALIFE-HACHEM S, Pegliasco J, Saada V, Hernandez E, et al
    Spontaneous molecular response of IDH2 acute myeloid leukemia.
    Ann Hematol. 2019 Dec 9. pii: 10.1007/s00277-019-03876.

  52. CAOCCI G, Greco M, Frau V, Asproni R, et al
    Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia.
    Ann Hematol. 2019 Dec 6. pii: 10.1007/s00277-019-03875.

  53. CHRISTIANSEN JS, Gaddh M, Wells J
    An uncommon presentation of chronic myeloid leukemia.
    Ann Hematol. 2019 Dec 2. pii: 10.1007/s00277-019-03869.

  54. WANG H, Zhang N, Wu X, Zheng X, et al
    Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Ann Hematol. 2019;98:2629-2639.
    PubMed     Abstract available

  55. BERGER T, Rozovski U, Moshe Y, Yaari S, et al
    Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
    Ann Hematol. 2019;98:2711-2717.
    PubMed     Abstract available

    November 2019
  56. KONISHI T, Doki N, Nagata A, Yamada Y, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia.
    Ann Hematol. 2019 Nov 30. pii: 10.1007/s00277-019-03865.
    PubMed     Abstract available

  57. SUN J, Yu W, Zhang X
    MEF2D-rearranged acute lymphoblastic leukemia resembles Burkitt lymphoma/leukemia.
    Ann Hematol. 2019 Nov 28. pii: 10.1007/s00277-019-03857.

  58. GAO MG, Ruan GR, Chang YJ, Liu YR, et al
    The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.
    Ann Hematol. 2019 Nov 25. pii: 10.1007/s00277-019-03861.
    PubMed     Abstract available

  59. NOGUEIRA FL, Martins NNN, Cardoso PSR, Murao M, et al
    Systemic mastocytosis associated with acute myeloid leukemia.
    Ann Hematol. 2019 Nov 25. pii: 10.1007/s00277-019-03806.

  60. LIANG JH, Zhu HY, Xu DM, Wang L, et al
    A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia.
    Ann Hematol. 2019 Nov 22. pii: 10.1007/s00277-019-03810.

  61. SALLES G, Bachy E, Smolej L, Simkovic M, et al
    Single-agent ibrutinib in RESONATE-2 and RESONATE versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Ann Hematol. 2019 Nov 19. pii: 10.1007/s00277-019-03830.
    PubMed     Abstract available

  62. PERI AM, Rossio R, Tafuri F, Benzecry V, et al
    Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Ann Hematol. 2019 Nov 18. pii: 10.1007/s00277-019-03837.

  63. CHONABAYASHI K, Yoshida Y, Kitawaki T, Nannya Y, et al
    Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis.
    Ann Hematol. 2019 Nov 14. pii: 10.1007/s00277-019-03838.

  64. BRAVO-PEREZ C, Pajares I, Muina B, Escobar H, et al
    Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
    Ann Hematol. 2019 Nov 11. pii: 10.1007/s00277-019-03829.

  65. TIRIBELLI M, Abruzzese E, Capodanno I, Sora F, et al
    Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
    Ann Hematol. 2019;98:2609-2611.

  66. MONTESINOS P, Bergua J, Infante J, Esteve J, et al
    Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
    Ann Hematol. 2019;98:2467-2483.
    PubMed     Abstract available

    October 2019
  67. ZHANG X, Jin J, Yu W
    ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia.
    Ann Hematol. 2019 Oct 21. pii: 10.1007/s00277-019-03804.

  68. WILLENBACHER E, Johrer K, Willenbacher W, Flogel B, et al
    Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.
    Ann Hematol. 2019 Oct 18. pii: 10.1007/s00277-019-03797.
    PubMed     Abstract available

  69. ALVAREZ-LARRAN A, Lopez-Guerra M, Rozman M, Correa JG, et al
    Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
    Ann Hematol. 2019;98:2319-2328.
    PubMed     Abstract available

  70. CRUGNOLA M, Castagnetti F, Breccia M, Ferrero D, et al
    Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
    Ann Hematol. 2019;98:2329-2338.
    PubMed     Abstract available

    September 2019
  71. QIN YZ, Jiang Q, Xu LP, Jiang H, et al
    The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2019 Sep 6. pii: 10.1007/s00277-019-03789.
    PubMed     Abstract available

  72. YOUNESIAN S, Shahkarami S, Ghaffari P, Alizadeh S, et al
    Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.
    Ann Hematol. 2019 Sep 5. pii: 10.1007/s00277-019-03775.
    PubMed     Abstract available

  73. WU X, Wang H, Deng J, Zheng X, et al
    Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
    Ann Hematol. 2019 Sep 3. pii: 10.1007/s00277-019-03774.
    PubMed     Abstract available

  74. CZYZEWSKI K, Styczynski J, Giebel S, Fraczkiewicz J, et al
    Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study.
    Ann Hematol. 2019;98:2197-2211.
    PubMed     Abstract available

  75. WASILEWSKA E, Kuziemski K, Niedoszytko M, Kaczorowska-Hac B, et al
    Impairment of lung diffusion capacity-a new consequence in the long-term childhood leukaemia survivors.
    Ann Hematol. 2019;98:2103-2110.
    PubMed     Abstract available

    August 2019
  76. LYAPICHEV KA, Kurt H, Sukswai N, Konoplev S, et al
    Chronic lymphocytic leukemia with plasmacytic differentiation.
    Ann Hematol. 2019 Aug 26. pii: 10.1007/s00277-019-03784.

  77. WU Q, Zhang R, Peng R, Fu Y, et al
    Clinician-friendly reports of molecular measurable residual disease monitoring in acute promyelocytic leukemia.
    Ann Hematol. 2019 Aug 24. pii: 10.1007/s00277-019-03782.
    PubMed     Abstract available

  78. MENDOZA H, Podoltsev NA, Siddon AJ, Gnanapandithan K, et al
    Acute myeloid leukemia presenting as bilateral adrenal hemorrhage.
    Ann Hematol. 2019 Aug 24. pii: 10.1007/s00277-019-03788.

  79. NG DB, Schiller G, Ha E
    Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib.
    Ann Hematol. 2019 Aug 13. pii: 10.1007/s00277-019-03780.

  80. KIDOGUCHI K, Kojima K, Yokoo M, Kimura S, et al
    BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis.
    Ann Hematol. 2019 Aug 10. pii: 10.1007/s00277-019-03779.

  81. GIEBEL S, Boumendil A, Labopin M, Seesaghur A, et al
    Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Ann Hematol. 2019 Aug 7. pii: 10.1007/s00277-019-03771.
    PubMed     Abstract available

  82. SUN YQ, Wang Y, Zhang XH, Xu LP, et al
    Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
    Ann Hematol. 2019;98:1877-1883.
    PubMed     Abstract available

  83. JYOTSANA N, Sharma A, Chaturvedi A, Budida R, et al
    Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Ann Hematol. 2019;98:1905-1918.
    PubMed     Abstract available

  84. MULLER M, Graf R, Kashofer K, Macher S, et al
    Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.
    Ann Hematol. 2019;98:2019-2020.

  85. MARRA A, Martino G, Ascani S, Martelli MP, et al
    Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma.
    Ann Hematol. 2019;98:2017-2018.

    July 2019
  86. SUH KJ, Shin DY, Kim I, Yoon SS, et al
    Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population.
    Ann Hematol. 2019 Jul 23. pii: 10.1007/s00277-019-03760.
    PubMed     Abstract available

  87. YAMASAKI S, Nitta H, Kondo E, Uchida N, et al
    Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
    Ann Hematol. 2019 Jul 20. pii: 10.1007/s00277-019-03759.
    PubMed     Abstract available

  88. JIANG H, Liu L, Guo T, Wu Y, et al
    Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
    Ann Hematol. 2019;98:1721-1732.
    PubMed     Abstract available

  89. STAMOULI M, Gkirkas K, Antoniades A, Kaklamanis L, et al
    Isolated extramedullary leukemic involvement of the heart presenting as fulminant heart failure.
    Ann Hematol. 2019;98:1775-1776.

    June 2019
  90. RODRIGUEZ-VEIGA R, Montesinos P, Boluda B, Lorenzo I, et al
    Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
    Ann Hematol. 2019 Jun 25. pii: 10.1007/s00277-019-03744.
    PubMed     Abstract available

  91. KAWASHIMA I, Kumagai T, Suzuki M, Suzuki J, et al
    Molecular response of CSF3R T618I harboring chronic neutrophilic leukemia after induction chemotherapy linked to cord blood transplantation.
    Ann Hematol. 2019 Jun 25. pii: 10.1007/s00277-019-03733.

  92. REYES-LEON A, Ramirez-Martinez M, Fernandez-Garcia D, Amaro-Munoz D, et al
    Variants in ARID5B gene are associated with the development of acute lymphoblastic leukemia in Mexican children.
    Ann Hematol. 2019 Jun 21. pii: 10.1007/s00277-019-03730.
    PubMed     Abstract available

  93. YANADA M, Mori J, Aoki J, Masuko M, et al
    Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia.
    Ann Hematol. 2019 Jun 15. pii: 10.1007/s00277-019-03736.
    PubMed     Abstract available

  94. YE P, Pei R, Jin J, Sun J, et al
    Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2019 Jun 14. pii: 10.1007/s00277-019-03723.
    PubMed     Abstract available

  95. RAM R, Amit O, Zuckerman T, Gurion R, et al
    Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ann Hematol. 2019 Jun 11. pii: 10.1007/s00277-019-03719.
    PubMed     Abstract available

  96. BOASMAN K, Simmonds MJ, Graham C, Saunthararajah Y, et al
    Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
    Ann Hematol. 2019;98:1529-1531.

  97. MCDONALD L, Fadalla K
    Synchronous follicular non-Hodgkin's lymphoma and hairy cell leukaemia: a case report.
    Ann Hematol. 2019;98:1517-1518.

  98. METAFUNI E, Criscuolo M, Spanu T, Sica S, et al
    Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience.
    Ann Hematol. 2019;98:1495-1497.

    May 2019
  99. REN X, Qin Y, Huang X, Zuo L, et al
    Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
    Ann Hematol. 2019 May 14. pii: 10.1007/s00277-019-03690.
    PubMed     Abstract available

  100. MOLICA M, Colafigli G, Scalzulli E, Alunni Fegatelli D, et al
    Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
    Ann Hematol. 2019 May 11. pii: 10.1007/s00277-019-03706.
    PubMed     Abstract available

  101. SHIN HJ, Min WS, Min YH, Cheong JW, et al
    Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
    Ann Hematol. 2019;98:1135-1147.
    PubMed     Abstract available

  102. MASHIMA K, Ikeda T, Kawaguchi SI, Toda Y, et al
    Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
    Ann Hematol. 2019;98:1127-1133.
    PubMed     Abstract available

  103. GARRASTAZUL-SANCHEZ MP, Vilches-Moreno M, Fernandez-Valle MC, Marchante-Cepillo I, et al
    Neutrophil faggot cells and inv(16): not such a fortuitous association?
    Ann Hematol. 2019;98:1293-1295.

  104. CAOCCI G, Mulas O, Abruzzese E, Iurlo A, et al
    Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Ann Hematol. 2019 May 1. pii: 10.1007/s00277-019-03705.
    PubMed     Abstract available

    April 2019
  105. SU L, Gao S, Tan Y, Lin H, et al
    CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Ann Hematol. 2019 Apr 30. pii: 10.1007/s00277-019-03699.
    PubMed     Abstract available

  106. AMMATUNA E, Huls G
    Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia?
    Ann Hematol. 2019 Apr 25. pii: 10.1007/s00277-019-03693.

  107. WANG Z, Yin C, Zhang W, Tang W, et al
    The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
    Ann Hematol. 2019 Apr 16. pii: 10.1007/s00277-019-03682.
    PubMed     Abstract available

  108. ZHANG X, Guo X
    Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Ann Hematol. 2019 Apr 12. pii: 10.1007/s00277-019-03674.

  109. ZHANG YL, Zhu Y, Xiao Q, Wang L, et al
    Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies.
    Ann Hematol. 2019;98:1009-1020.
    PubMed     Abstract available

  110. BIANCHI M, Heim D, Lengerke C, Halter J, et al
    Cyclosporine levels > 195 mug/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2019;98:971-977.
    PubMed     Abstract available

  111. XHAARD A, Porcher R, Bergeron A, Alanio A, et al
    Primary antifungal prophylaxis with micafungin after allogeneic hematopoietic stem cell transplantation: a monocentric prospective study.
    Ann Hematol. 2019;98:1033-1035.

    March 2019
  112. HELBIG G, Spalek A, Wieczorkiewicz-Kabut A, Markiewicz M, et al
    Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
    Ann Hematol. 2019 Mar 27. pii: 10.1007/s00277-019-03679.
    PubMed     Abstract available

  113. LINS MM, Mello MJG, Ribeiro RC, De Camargo B, et al
    Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Ann Hematol. 2019 Mar 26. pii: 10.1007/s00277-019-03661.
    PubMed     Abstract available

  114. KONISHI T, Doki N, Kishida Y, Nagata A, et al
    Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission.
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03668.

  115. KESSLER T, Koschmieder S, Schliemann C, Crysandt M, et al
    Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03651.
    PubMed     Abstract available

  116. GAJENDRA S, Yadav AK, Chugh B, Sood N, et al
    Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukemia.
    Ann Hematol. 2019 Mar 11. pii: 10.1007/s00277-019-03660.

  117. KARAI B, Habok M, Remenyi G, Rejto L, et al
    A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.
    Ann Hematol. 2019 Mar 4. pii: 10.1007/s00277-019-03642.
    PubMed     Abstract available

  118. KUNZ F, Kontopoulou E, Reinhardt K, Soldierer M, et al
    Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
    Ann Hematol. 2019;98:595-603.
    PubMed     Abstract available

  119. OYAKE T, Takemasa-Fujisawa Y, Sugawara N, Mine T, et al
    Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
    Ann Hematol. 2019 Mar 1. pii: 10.1007/s00277-019-03634.
    PubMed     Abstract available

    February 2019
  120. DULUCQ S, Etienne G, Morisset S, Klein E, et al
    Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Ann Hematol. 2019 Feb 23. pii: 10.1007/s00277-019-03633.
    PubMed     Abstract available

  121. YSEBAERT L, Larcher M, Compaci G, Oberic L, et al
    Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
    Ann Hematol. 2019 Feb 18. pii: 10.1007/s00277-019-03631.
    PubMed     Abstract available

  122. XIE W, Hu S, Xu J, Chen Z, et al
    Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
    Ann Hematol. 2019 Feb 13. pii: 10.1007/s00277-019-03637.
    PubMed     Abstract available

  123. GAO XN, Lin J, Wang LJ, Li F, et al
    Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Ann Hematol. 2019 Feb 12. pii: 10.1007/s00277-019-03636.
    PubMed     Abstract available

  124. MINA A, Shune L, Abdelhakim H, Lin TL, et al
    Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment.
    Ann Hematol. 2019;98:481-489.
    PubMed     Abstract available

  125. PICARDI M, Della Pepa R, Giordano C, Pugliese N, et al
    (1-3)-beta-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
    Ann Hematol. 2019;98:527-531.

    January 2019
  126. KANAKASETTY GB, R C, K C L, Dasappa L, et al
    Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.
    Ann Hematol. 2019 Jan 29. pii: 10.1007/s00277-019-03600.
    PubMed     Abstract available

  127. CHEUNG E, Perissinotti AJ, Bixby DL, Burke PW, et al
    The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
    Ann Hematol. 2019 Jan 21. pii: 10.1007/s00277-019-03606.
    PubMed     Abstract available

  128. OKUYAMA S, Nito T, Yanagawa N, Tajima K, et al
    Giant cellulitis-like Sweet syndrome as an initial clinical presentation of acute myeloblastic leukemia with t(6;9)(p23;q34): DEK-CAN and internal duplications of FMS-like tyrosine kinase 3.
    Ann Hematol. 2019 Jan 18. pii: 10.1007/s00277-019-03613.

  129. LIU B, Wang Y, Zhou C, Wei H, et al
    Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.
    Ann Hematol. 2019 Jan 11. pii: 10.1007/s00277-019-03594.
    PubMed     Abstract available

  130. LIU L, Zhang X, Qiu H, Tang X, et al
    HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/high-risk acute myeloid leukemia.
    Ann Hematol. 2019 Jan 10. pii: 10.1007/s00277-018-3583.
    PubMed     Abstract available

  131. DOPPELHAMMER M, Fraccaroli A, Prevalsek D, Bucklein V, et al
    Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Ann Hematol. 2019 Jan 8. pii: 10.1007/s00277-019-03593.
    PubMed     Abstract available

  132. STRATMANN JA, von Rose AB, Koschade S, Wendelin K, et al
    Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.
    Ann Hematol. 2019 Jan 6. pii: 10.1007/s00277-018-03590.
    PubMed     Abstract available

  133. ZHANG Y, Zhang Y, Chen Q, Tang G, et al
    Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years.
    Ann Hematol. 2019 Jan 3. pii: 10.1007/s00277-018-3584.
    PubMed     Abstract available

  134. KAWASHIMA N, Akashi A, Nagata Y, Kihara R, et al
    Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Ann Hematol. 2019;98:83-91.
    PubMed     Abstract available

  135. XIAOSU Z, Leqing C, Yazhen Q, Yu W, et al
    Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFbeta/MYH11 gene expression.
    Ann Hematol. 2019;98:73-81.
    PubMed     Abstract available

  136. GAO XN, Lin J, Wang SH, Huang WR, et al
    Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
    Ann Hematol. 2019;98:185-193.
    PubMed     Abstract available

  137. WANNER D, Bohn JP, Rudzki J, Stockhammer G, et al
    Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Ann Hematol. 2019;98:205-207.

    December 2018
  138. BUCCHERI V, Barreto WG, Fogliatto LM, Capra M, et al
    Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Ann Hematol. 2018;97:2269-2278.
    PubMed     Abstract available

  139. CASTELLI R, Rossi V, Della Porta MG, Schiavon R, et al
    Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant.
    Ann Hematol. 2018;97:2523-2525.

    November 2018
  140. QASRAWI A, Bahaj W, Qasrawi L, Abughanimeh O, et al
    Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Ann Hematol. 2018 Nov 23. pii: 10.1007/s00277-018-3562.
    PubMed     Abstract available

  141. ISHIDA H, Iguchi A, Aoe M, Takahashi T, et al
    Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
    Ann Hematol. 2018 Nov 17. pii: 10.1007/s00277-018-3554.
    PubMed     Abstract available

  142. DE BARROS S, Vayr F, Despas F, Strumia M, et al
    The impact of chronic myeloid leukemia on employment: the French prospective study.
    Ann Hematol. 2018 Nov 17. pii: 10.1007/s00277-018-3549.
    PubMed     Abstract available

  143. GARCIA-GUTIERREZ V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, et al
    Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
    Ann Hematol. 2018 Nov 16. pii: 10.1007/s00277-018-3507.
    PubMed     Abstract available

  144. PEJSA V, Lucijanic M, Jonjic Z, Prka Z, et al
    Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia.
    Ann Hematol. 2018 Nov 13. pii: 10.1007/s00277-018-3552.

  145. BODDU P, Chihara D, Masarova L, Pemmaraju N, et al
    The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Ann Hematol. 2018;97:2071-2080.
    PubMed     Abstract available

  146. SHALLIS RM, Xu ML, Curtis SA, Medoff E, et al
    Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
    Ann Hematol. 2018;97:2245-2248.

  147. BRUNELLO L, Passera R, Dellacasa CM, Giaccone L, et al
    Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients.
    Ann Hematol. 2018;97:2205-2215.
    PubMed     Abstract available

    October 2018
  148. LI Y, Shao H, Fu B
    Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis.
    Ann Hematol. 2018 Oct 30. pii: 10.1007/s00277-018-3537.

  149. ZAPRAZNA K, Reblova K, Svobodova V, Radova L, et al
    Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Oct 27. pii: 10.1007/s00277-018-3520.
    PubMed     Abstract available

  150. NAKAMURA N, Ninomiya S, Matsumoto T, Nakamura H, et al
    Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia.
    Ann Hematol. 2018 Oct 19. pii: 10.1007/s00277-018-3508.
    PubMed     Abstract available

  151. RANI L, Gogia A, Singh V, Kumar L, et al
    Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
    Ann Hematol. 2018 Oct 18. pii: 10.1007/s00277-018-3525.
    PubMed     Abstract available

  152. LEE AC, Leo SW
    Juvenile myelomonocytic leukemia: a surprising cause of peri-orbital tumor and squint.
    Ann Hematol. 2018 Oct 12. pii: 10.1007/s00277-018-3510.

  153. KHALIL MMI, Messner HA, Lipton JH, Kim DD, et al
    Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Ann Hematol. 2018;97:1975-1985.
    PubMed     Abstract available

  154. EGLE A, Steurer M, Melchardt T, Weiss L, et al
    Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Ann Hematol. 2018;97:1825-1839.
    PubMed     Abstract available

  155. FORBRIGGER Z, Kuhle S, Brown MM, Moorehead PC, et al
    The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study.
    Ann Hematol. 2018;97:1903-1908.
    PubMed     Abstract available

  156. BARON F, Stevens-Kroef M, Kicinski M, Meloni G, et al
    Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
    Ann Hematol. 2018;97:1785-1795.
    PubMed     Abstract available

  157. BARONI F, Marraccini C, Merolle L, Piccagli V, et al
    Red blood cells metabolome changes upon treatment with different X-ray irradiation doses.
    Ann Hematol. 2018;97:1909-1917.
    PubMed     Abstract available

  158. ISOBE Y, Uemura Y, Uchida A, Miura I, et al
    A portion of expanded granular lymphocytes cause pure white cell aplasia?
    Ann Hematol. 2018;97:1995-1997.

    September 2018
  159. URESHINO H, Kusaba K, Kidoguchi K, Sano H, et al
    Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Sep 27. pii: 10.1007/s00277-018-3502.
    PubMed     Abstract available

  160. JUNG SH, Lee SR, Yang DH, Lee S, et al
    Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
    Ann Hematol. 2018 Sep 26. pii: 10.1007/s00277-018-3495.
    PubMed     Abstract available

  161. STEIN AS, Schiller G, Benjamin R, Jia C, et al
    Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
    Ann Hematol. 2018 Sep 20. pii: 10.1007/s00277-018-3497.
    PubMed     Abstract available

  162. VAN DE LOUW A, Lewis AM, Yang Z
    Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure.
    Ann Hematol. 2018 Sep 14. pii: 10.1007/s00277-018-3494.
    PubMed     Abstract available

  163. ELBAEK MV, Sorensen AL, Hasselbalch HC
    Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?
    Ann Hematol. 2018 Sep 4. pii: 10.1007/s00277-018-3489.
    PubMed     Abstract available

  164. TIMMERS NKLM, de Maar JS, van Kruijsdijk RCM, Klein SK, et al
    Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature.
    Ann Hematol. 2018;97:1627-1632.
    PubMed     Abstract available

  165. HATTA Y, Mizuta S, Matsuo K, Ohtake S, et al
    Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Ann Hematol. 2018;97:1535-1545.
    PubMed     Abstract available

    August 2018
  166. WANG H, Li Y, Lv N, Li Y, et al
    Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Ann Hematol. 2018 Aug 6. pii: 10.1007/s00277-018-3464.
    PubMed     Abstract available

  167. SCHULER E, Zadrozny N, Blum S, Schroeder T, et al
    Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3466.
    PubMed     Abstract available

  168. XIAO H, Li L, Pang Y, Wu Y, et al
    Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3453.
    PubMed     Abstract available

  169. MONTORO J, Gallur L, Merchan B, Molero A, et al
    Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Ann Hematol. 2018;97:1349-1356.
    PubMed     Abstract available

  170. DE ALVARENGA EC, Silva WN, Vasconcellos R, Paredes-Gamero EJ, et al
    Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression.
    Ann Hematol. 2018 Aug 1. pii: 10.1007/s00277-018-3463.
    PubMed     Abstract available

  171. PINTO AL, Ferreira G, Carda JP, Gomes M, et al
    Isolated Richter's syndrome of the brain: diagnosis in the eye of the beholder.
    Ann Hematol. 2018;97:1509-1511.

  172. CASTELLI A, Mosca-Siez ML, Riccomagno P, Patriarca A, et al
    Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report.
    Ann Hematol. 2018;97:1485-1486.

  173. FUREDER W, Sperr WR, Gleixner K, Thalhammer R, et al
    Major response of PNH to an AML chemotherapy protocol.
    Ann Hematol. 2018;97:1487-1488.

  174. JIN Z, Xiang R, Qing K, Li X, et al
    The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Ann Hematol. 2018;97:1327-1335.
    PubMed     Abstract available

    July 2018
  175. SCHNEIDAWIND C, Hagmaier V, Faul C, Kanz L, et al
    Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
    Ann Hematol. 2018 Jul 31. pii: 10.1007/s00277-018-3454.
    PubMed     Abstract available

  176. GU B, Zhang X, Chen G, Wu X, et al
    Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia.
    Ann Hematol. 2018 Jul 23. pii: 10.1007/s00277-018-3428.
    PubMed     Abstract available

  177. PARK E, Jue MS
    Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Jul 21. pii: 10.1007/s00277-018-3444.

  178. BURNS TF, Loo EY, Bengtson EM, Bao L, et al
    Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2018 Jul 20. pii: 10.1007/s00277-018-3399.

  179. ZHANG G, Zhang L, Yang X, Zhang X, et al
    High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Jul 18. pii: 10.1007/s00277-018-3440.

  180. ZAPPASODI P, Marbello L, Borlenghi E, Fumagalli M, et al
    Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Ann Hematol. 2018 Jul 15. pii: 10.1007/s00277-018-3424.
    PubMed     Abstract available

  181. LIN XJ, Dai HP, Wang AJ, Chen F, et al
    Effects of preemptive interferon-alpha monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study.
    Ann Hematol. 2018 Jul 11. pii: 10.1007/s00277-018-3429.
    PubMed     Abstract available

  182. DUGGE R, Kreipe H, Rosenwald A, Lehmann U, et al
    Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis.
    Ann Hematol. 2018 Jul 7. pii: 10.1007/s00277-018-3434.

  183. KONUMA T, Mizuno S, Kondo T, Yamaguchi H, et al
    Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3419.
    PubMed     Abstract available

  184. SUEDA S, Nakayama S, Adachi T, Ohashi Y, et al
    Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3426.

  185. MEGIAS-VERICAT JE, Martinez-Cuadron D, Sanz MA, Montesinos P, et al
    Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
    Ann Hematol. 2018;97:1115-1153.
    PubMed     Abstract available

  186. VANDER MEEREN S, Heyrman B, Renmans W, Bakkus M, et al
    Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.
    Ann Hematol. 2018;97:1219-1227.
    PubMed     Abstract available

    June 2018
  187. KRISTON C, Plander M, Mark A, Sebestyen A, et al
    In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3410.
    PubMed     Abstract available

  188. OSORIO S, Escudero-Vilaplana V, Gomez-Centurion I, Perez-Lopez R, et al
    Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3413.
    PubMed     Abstract available

  189. KUBOTA Y, Kamachi K, Wakayama K, Kitamura H, et al
    Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3408.

  190. CICCONI L, Breccia M, Franceschini L, Latagliata R, et al
    Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3400.
    PubMed     Abstract available

  191. FUJIOKA I, Takaku T, Iriyama N, Tokuhira M, et al
    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3412.
    PubMed     Abstract available

  192. STRUGOV V, Stadnik E, Virts Y, Andreeva T, et al
    Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3409.
    PubMed     Abstract available

  193. ZHU Y, Gao Q, Du J, Hu J, et al
    Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3414.
    PubMed     Abstract available

  194. FEDERMANN B, Mueller MR, Steinhilber J, Horger MS, et al
    Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales.
    Ann Hematol. 2018 Jun 12. pii: 10.1007/s00277-018-3390.
    PubMed     Abstract available

  195. MAURILLO L, Buccisano F, Spagnoli A, Voso MT, et al
    Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Ann Hematol. 2018 Jun 10. pii: 10.1007/s00277-018-3374.
    PubMed     Abstract available

  196. LIU H, Wang SA, Schlette EJ, Xu J, et al
    Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3389.
    PubMed     Abstract available

  197. SAKELLARI I, Gavriilaki E, Chatziioannou K, Papathanasiou M, et al
    Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3383.
    PubMed     Abstract available

  198. SAHIN U, Dalva K, Gungor F, Ustun C, et al
    Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Ann Hematol. 2018;97:1027-1039.
    PubMed     Abstract available

  199. ZERKALENKOVA E, Panfyorova A, Kazakova A, Baryshev P, et al
    Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.
    Ann Hematol. 2018;97:977-988.
    PubMed     Abstract available

  200. ZHAO X, Wang Z, Ruan G, Liu Y, et al
    Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Ann Hematol. 2018;97:967-975.
    PubMed     Abstract available

  201. STRENGER V, Merth G, Lackner H, Aberle SW, et al
    Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years.
    Ann Hematol. 2018;97:989-998.
    PubMed     Abstract available

  202. ZAUNER F, Tayeb S, Panagiota V, Rababah M, et al
    Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?
    Ann Hematol. 2018;97:1111-1113.

    May 2018
  203. IWASHIGE A, Hirosawa M, Tsukada J
    Hairy cell leukemia presenting with progressive pericarditis and pleuritis.
    Ann Hematol. 2018 May 30. pii: 10.1007/s00277-018-3378.

  204. MOLICA M, Scalzulli E, Colafigli G, Fegatelli DA, et al
    Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Ann Hematol. 2018 May 27. pii: 10.1007/s00277-018-3375.
    PubMed     Abstract available

  205. BILL M, Grimm J, Jentzsch M, Kloss L, et al
    Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Ann Hematol. 2018 May 22. pii: 10.1007/s00277-018-3373.
    PubMed     Abstract available

  206. ALLAIN EP, Venzl K, Caron P, Turcotte V, et al
    Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
    Ann Hematol. 2018 May 21. pii: 10.1007/s00277-018-3356.
    PubMed     Abstract available

  207. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.
    Ann Hematol. 2018 May 8. pii: 10.1007/s00277-018-3350.

  208. MIAO Y, Miao Y, Shi K, Sun Q, et al
    A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion.
    Ann Hematol. 2018 May 7. pii: 10.1007/s00277-018-3359.
    PubMed     Abstract available

  209. MARHALL A, Heidel F, Fischer T, Ronnstrand L, et al
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018;97:773-780.
    PubMed     Abstract available

  210. VIGNOLI A, Marchetti M, Falanga A
    Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins.
    Ann Hematol. 2018 May 1. pii: 10.1007/s00277-018-3343.
    PubMed     Abstract available

    April 2018
  211. HONG Y, Zhao X, Qin Y, Zhou S, et al
    The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 28. pii: 10.1007/s00277-018-3338.
    PubMed     Abstract available

  212. COLTOFF A, Houldsworth J, Keyzner A, Renteria AS, et al
    Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Ann Hematol. 2018 Apr 27. pii: 10.1007/s00277-018-3330.
    PubMed     Abstract available

  213. ZHANG J, Shi J, Zhang G, Zhang X, et al
    BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3331.
    PubMed     Abstract available

  214. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3340.
    PubMed     Abstract available

  215. BRECCIA M, Abruzzese E, Castagnetti F, Bonifacio M, et al
    Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
    Ann Hematol. 2018 Apr 19. pii: 10.1007/s00277-018-3337.
    PubMed     Abstract available

  216. WANG X, Zhang L, Zhao F, Xu R, et al
    Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
    Ann Hematol. 2018 Apr 13. pii: 10.1007/s00277-018-3315.
    PubMed     Abstract available

  217. LO WJ, Lin CL, Chang YC, Bai LY, et al
    Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow-derived mesenchymal stromal stem cells.
    Ann Hematol. 2018;97:697-707.
    PubMed     Abstract available

  218. SCAPPATICCI GB, Marini BL, Nachar VR, Uebel JR, et al
    Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Ann Hematol. 2018;97:573-584.
    PubMed     Abstract available

    March 2018
  219. SUZUKI Y, Honda A, Nakazaki K, Mizuno H, et al
    Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.
    Ann Hematol. 2018 Mar 26. pii: 10.1007/s00277-018-3300.

  220. SAINI NY, Bathini V
    Large granular lymphocytic leukemia-associated peripheral neuropathy.
    Ann Hematol. 2018 Mar 22. pii: 10.1007/s00277-018-3310.

  221. KHAN M, Muzzafar T, Kantarjian H, Badar I, et al
    Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3289.
    PubMed     Abstract available

  222. PIATOPOULOU D, Avgeris M, Drakaki I, Marmarinos A, et al
    Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3292.
    PubMed     Abstract available

  223. KIM DW, Saussele S, Williams LA, Mohamed H, et al
    Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3295.
    PubMed     Abstract available

  224. KHAN M, Siddiqi R, Naqvi K
    An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL).
    Ann Hematol. 2018 Mar 15. pii: 10.1007/s00277-018-3297.
    PubMed     Abstract available

  225. HA J, Kim B, Hahn S, Lee ST, et al
    A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
    Ann Hematol. 2018 Mar 8. pii: 10.1007/s00277-018-3291.

  226. PARK S, Choi H, Kim HJ, Ahn JS, et al
    Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
    Ann Hematol. 2018 Mar 2. pii: 10.1007/s00277-018-3260.
    PubMed     Abstract available

  227. HIDALGO LOPEZ JE, Carballo-Zarate A, Verstovsek S, Wang SA, et al
    Bone marrow findings in blast phase of polycythemia vera.
    Ann Hematol. 2018;97:425-434.
    PubMed     Abstract available

  228. HARADA K, Doki N, Miyazaki Y, Wakita A, et al
    Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
    Ann Hematol. 2018 Mar 1. pii: 10.1007/s00277-018-3281.

    February 2018
  229. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 23. pii: 10.1007/s00277-018-3277.
    PubMed     Abstract available

  230. BRECCIA M, Palandri F, Luciano L, Benevolo G, et al
    Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
    Ann Hematol. 2018 Feb 22. pii: 10.1007/s00277-018-3258.
    PubMed     Abstract available

  231. SHIMOMURA Y, Hara M, Katoh D, Hashimoto H, et al
    Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Ann Hematol. 2018 Feb 17. pii: 10.1007/s00277-018-3278.
    PubMed     Abstract available

  232. ZHAO HY, Song Y, Cao XN, Qin YZ, et al
    Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.
    Ann Hematol. 2018 Feb 10. pii: 10.1007/s00277-018-3253.
    PubMed     Abstract available

  233. NAKAYAMA S, Matsuda M, Adachi T, Sueda S, et al
    Adult T cell leukemia/lymphoma with different pathological features in each tumor site.
    Ann Hematol. 2018 Feb 9. pii: 10.1007/s00277-018-3272.

  234. SUZUKI Y, Koya J, Ebisawa K, Abe H, et al
    Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3248.

  235. WEI G, Hu Y, Pu C, Yu J, et al
    CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3246.
    PubMed     Abstract available

  236. DI BLASI R, Cattaneo C, Lewis RE, Tumbarello M, et al
    Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3252.
    PubMed     Abstract available

  237. TACHIKI L, Dong ZM, Burwick N
    Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3261.

  238. MORITA K, Koya J, Toya T, Nakamura F, et al
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3263.

  239. FUJIMI A, Nagamachi Y, Yamauchi N
    Extramedullary involvement of the stomach presenting as multiple white elevations in the initial diagnosis of chronic myeloid leukemia treated with dasatinib.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3268.

  240. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 2. pii: 10.1007/s00277-018-3229.
    PubMed     Abstract available

  241. MELLINGHOFF SC, Panse J, Alakel N, Behre G, et al
    Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Ann Hematol. 2018;97:197-207.
    PubMed     Abstract available

  242. DUONG VH, Padron E, Al Ali NH, Lancet JE, et al
    The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Ann Hematol. 2018;97:247-254.
    PubMed     Abstract available

  243. SCHROEDER T, Rautenberg C, Kruger W, Platzbecker U, et al
    Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2018;97:335-342.
    PubMed     Abstract available

  244. MINODA S, Akasaka T, Okanoue Y, Honjo G, et al
    Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3235.

  245. SHAHKARAMI S, Mehrasa R, Younesian S, Yaghmaie M, et al
    Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3230.
    PubMed     Abstract available

  246. CHAN TSY, Kwong YL
    Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy.
    Ann Hematol. 2018;97:371-373.

    January 2018
  247. SAEED OAM, Longe HO, Zhou J
    T cell large granular lymphocytic leukemia, a rare form of post lung transplant lymphoproliferative disorder.
    Ann Hematol. 2018 Jan 8. pii: 10.1007/s00277-017-3213.

  248. BEN LAKHAL R, Ghedira H, Bellaaj H, Ben Youssef Y, et al
    Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ann Hematol. 2018 Jan 6. pii: 10.1007/s00277-017-3224.
    PubMed     Abstract available

  249. KAMEDA K, Kako S, Hayakawa J, Akahoshi Y, et al
    Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.
    Ann Hematol. 2018;97:169-179.
    PubMed     Abstract available

    December 2017
  250. ZHAO H, Zhao Y, Zhang Y, Hou J, et al
    Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Ann Hematol. 2017 Dec 30. pii: 10.1007/s00277-017-3216.
    PubMed     Abstract available

  251. SADEGHI N, Li HC
    MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Ann Hematol. 2017 Dec 28. pii: 10.1007/s00277-017-3219.

  252. YANG J, Cai Y, Jiang J, Wan L, et al
    Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Ann Hematol. 2017 Dec 18. pii: 10.1007/s00277-017-3204.
    PubMed     Abstract available

  253. HARADA K, Doki N, Hagino T, Miyawaki S, et al
    Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
    Ann Hematol. 2017 Dec 2. pii: 10.1007/s00277-017-3156.
    PubMed     Abstract available

    November 2017
  254. HILMI M, Bally C, Burns R, Lorillon G, et al
    Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
    Ann Hematol. 2017 Nov 23. pii: 10.1007/s00277-017-3190.

  255. HASSANI S, Khaleghian A, Ahmadian S, Alizadeh S, et al
    Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Ann Hematol. 2017 Nov 20. doi: 10.1007/s00277-017-3163.
    PubMed     Abstract available

  256. PRATS-MARTIN C, Jimenez-Guerrero P, Morales-Camacho RM, Caballero-Velazquez T, et al
    KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Nov 18. doi: 10.1007/s00277-017-3187.

  257. SHAO H, Yang Q, Zhang P, Liu H, et al
    Simultaneous occurrence of two distinct leukemic clones with PML-RARalpha and RUNX1-RUNX1T1 in a case of acute myeloid leukemia.
    Ann Hematol. 2017 Nov 9. doi: 10.1007/s00277-017-3169.

  258. LORENZANA N, Avila LF, Alonso S, Colado E, et al
    The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
    Ann Hematol. 2017;96:1833-1840.
    PubMed     Abstract available

    October 2017
  259. NASSEREDDINE S, Lap CJ, Haroun F, Tabbara I, et al
    The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3161.
    PubMed     Abstract available

  260. NAGEL G, Weber D, Fromm E, Erhardt S, et al
    Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3150.
    PubMed     Abstract available

  261. YANG D, Zhang X, Zhang X, Xu Y, et al
    The progress and current status of immunotherapy in acute myeloid leukemia.
    Ann Hematol. 2017 Oct 28. doi: 10.1007/s00277-017-3148.
    PubMed     Abstract available

  262. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2017 Oct 27. doi: 10.1007/s00277-017-3158.
    PubMed     Abstract available

  263. KHAN M, Siddiqi R, Thompson PA
    Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
    Ann Hematol. 2017 Oct 23. doi: 10.1007/s00277-017-3149.
    PubMed     Abstract available

  264. GUTIERREZ-AGUIRRE CH, Flores-Jimenez JA, Alatorre-Ricardo J, Cantu-Rodriguez OG, et al
    The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.
    Ann Hematol. 2017 Oct 13. doi: 10.1007/s00277-017-3142.
    PubMed     Abstract available

  265. TERADA K, Yamaguchi H, Ueki T, Usuki K, et al
    Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
    Ann Hematol. 2017 Oct 4. doi: 10.1007/s00277-017-3143.
    PubMed     Abstract available

  266. IURLO A, Galimberti S, Abruzzese E, Annunziata M, et al
    Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3144.
    PubMed     Abstract available

  267. YANAGIHARA T, Ikematsu Y, Kato K, Yonekawa A, et al
    Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3146.

  268. SAMADI O, Breunis H, Sandoval J, Akilan K, et al
    Return to work and work-related disability among AML survivors.
    Ann Hematol. 2017;96:1625-1633.
    PubMed     Abstract available

  269. HANSSON L, Asklid A, Diels J, Eketorp-Sylvan S, et al
    Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Ann Hematol. 2017;96:1681-1691.
    PubMed     Abstract available

  270. HAMADOU WS, Mani R, Besbes S, Bourdon V, et al
    GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
    Ann Hematol. 2017;96:1635-1639.
    PubMed     Abstract available

    September 2017
  271. HOU J, Wang S, Zhang Y, Fan D, et al
    Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Ann Hematol. 2017 Sep 22. doi: 10.1007/s00277-017-3130.
    PubMed     Abstract available

  272. JAWHAR M, Naumann N, Schwaab J, Baurmann H, et al
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Ann Hematol. 2017;96:1463-1470.
    PubMed     Abstract available

  273. HAROUN F, Solola SA, Nassereddine S, Tabbara I, et al
    PD-1 signaling and inhibition in AML and MDS.
    Ann Hematol. 2017;96:1441-1448.
    PubMed     Abstract available

    August 2017
  274. SHAO H, Yang Q, Wu C, Cen J, et al
    Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Ann Hematol. 2017 Aug 24. doi: 10.1007/s00277-017-3110.

  275. OH SB, Park SW, Chung JS, Lee WS, et al
    Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Ann Hematol. 2017 Aug 21. doi: 10.1007/s00277-017-3104.
    PubMed     Abstract available

  276. IURLO A, Bucelli C, Cattaneo D, Orofino N, et al
    Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3105.

  277. LOU Y, Ma Y, Sun J, Suo S, et al
    Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3096.
    PubMed     Abstract available

  278. ZHAO Y, Wang J, Luo Y, Shi J, et al
    Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Ann Hematol. 2017;96:1353-1360.
    PubMed     Abstract available

  279. SAGLIO G, le Coutre P, Cortes J, Mayer J, et al
    Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
    Ann Hematol. 2017;96:1303-1313.
    PubMed     Abstract available

  280. EREN R, Dogu MH, Emir S, Huq GE, et al
    Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.
    Ann Hematol. 2017;96:1315-1321.
    PubMed     Abstract available

    July 2017
  281. YUI S, Kurosawa S, Yamaguchi H, Kanamori H, et al
    D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Ann Hematol. 2017 Jul 31. doi: 10.1007/s00277-017-3074.
    PubMed     Abstract available

  282. NISCOLA P, Tendas A, Abruzzese E, Caravita T, et al
    Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Ann Hematol. 2017 Jul 12. doi: 10.1007/s00277-017-3064.

  283. THOMAY K, Fedder C, Hofmann W, Kreipe H, et al
    Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Ann Hematol. 2017 Jul 9. doi: 10.1007/s00277-017-3055.
    PubMed     Abstract available

  284. VENTURA FERREIRA MS, Crysandt M, Ziegler P, Hummel S, et al
    Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.
    Ann Hematol. 2017 Jul 3. doi: 10.1007/s00277-017-3049.
    PubMed     Abstract available

  285. RODRIGUEZ-VEIGA R, Igual B, Montesinos P, Tormo M, et al
    Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
    Ann Hematol. 2017;96:1077-1084.
    PubMed     Abstract available

  286. KAUR V, Swami A
    Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Ann Hematol. 2017;96:1175-1184.
    PubMed     Abstract available

    June 2017
  287. URESHINO H, Kamachi K, Miyahara M
    Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients.
    Ann Hematol. 2017 Jun 27. doi: 10.1007/s00277-017-3052.

  288. BALDUCCI E, Nivaggioni V, Boudjarane J, Bouriche L, et al
    Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.
    Ann Hematol. 2017 Jun 20. doi: 10.1007/s00277-017-3050.

  289. HEUSER M, Gabdoulline R, Loffeld P, Dobbernack V, et al
    Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Jun 13. doi: 10.1007/s00277-017-3027.
    PubMed     Abstract available

  290. JONSSON S, Olsson B, Soderberg J, Wadenvik H, et al
    Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3024.

  291. DE LACERDA MP, Guedes NR, Yamakawa PE, Pereira AD, et al
    Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with (del17p).
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3039.

  292. ABLA O, Ribeiro RC, Testi AM, Montesinos P, et al
    Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Ann Hematol. 2017 Jun 8. doi: 10.1007/s00277-017-3042.
    PubMed     Abstract available

  293. MUKHERJEE S, Ibrahimi S, John S, Adnan MM, et al
    Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia.
    Ann Hematol. 2017 Jun 3. doi: 10.1007/s00277-017-3037.
    PubMed     Abstract available

  294. OKA S, Ono K, Nohgawa M
    Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Ann Hematol. 2017 Jun 2. doi: 10.1007/s00277-017-3032.

  295. BRAULKE F, Schulz X, Germing U, Schuler E, et al
    Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Ann Hematol. 2017;96:887-894.
    PubMed     Abstract available

  296. CHOI DC, Tremblay D, Iancu-Rubin C, Mascarenhas J, et al
    Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
    Ann Hematol. 2017;96:919-927.
    PubMed     Abstract available

    May 2017
  297. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2017 May 20. doi: 10.1007/s00277-017-3025.

  298. HAEN SP, Groh C, Schumm M, Backert L, et al
    Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Ann Hematol. 2017;96:817-827.
    PubMed     Abstract available

    April 2017
  299. MATERN S, Schmidt E, Hartmann D, Schliemann C, et al
    Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3000.

  300. SANCHEZ R, Ayala R, Alonso RA, Martinez MP, et al
    Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3002.
    PubMed     Abstract available

  301. KOYA J, Ibaraki T, Yamazaki I, Nakamura F, et al
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 2017 Apr 19. doi: 10.1007/s00277-017-2987.

  302. ESPINOSA LARA P, Quiros Redondo V, Aguado Lobo M, Jimenez-Reyes J, et al
    Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol.
    Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992.

  303. SHUSTIK C, Bence-Bruckler I, Delage R, Owen CJ, et al
    Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2017 Apr 7. doi: 10.1007/s00277-017-2982.
    PubMed     Abstract available

    March 2017
  304. DUNOYER-GEINDRE S, Rivier-Cordey AS, Tsopra O, Lecompte T, et al
    Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta.
    Ann Hematol. 2017 Mar 25. doi: 10.1007/s00277-017-2970.
    PubMed     Abstract available

  305. BOTH A, Krauter J, Damm F, Thol F, et al
    The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
    Ann Hematol. 2017 Mar 22. doi: 10.1007/s00277-017-2967.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.